·88·中国现代药物应用2024年4月第18卷第8期ChinJModDrugAppl,Apr2024,Vol.18,No.8依达拉奉右莰醇在急性缺血性脑卒中患者中的应用分析贾晓艳【摘要】目的分析依达拉奉右莰醇在急性缺血性脑卒中(AIS)患者中的应用效果。方法99例急性缺血性脑卒中患者,根据随机数字表法分为研究组(50例)与对照组(49例)。两组均行静脉溶栓治疗,对照组溶栓后接受常规对症治疗,研究组在对照组的基础上联合应用依达拉奉右莰醇治疗。比较两组患者的临床疗效,氧化应激指标［丙二醛(MDA)、超氧化物歧化酶(SOD)］,不良反应发生情况。结果研究组总有效率94.00%高于对照组的75.51%(P<0.05)。治疗前,两组MDA、SOD水平对比,结果未见差异性(P>0.05)；治疗后,研究组MDA水平(4.55±0.56)μmol/L低于对照组的(6.40±0.89)μmol/L,SOD水平(95.65±12.66)U/ml高于对照组的(79.50±13.06)U/ml(P<0.05)。两组不良反应发生率比较未见差异性(P>0.05)。结论依达拉奉右莰醇能够有效改善急性缺血性脑卒中患者的神经功能,抑制氧化应激反应,安全性较佳,具有临床应用与推广价值。【关键词】依达拉奉右莰醇；急性缺血性脑卒中；神经功能DOI：10.14164/j.cnki.cn11-5581/r.2024.08.023ApplicationofedaravoneanddexborneolinpatientswithacuteischemicstrokeJIAXiao-yan.DepartmentofPharmacy,YantaiHarbourHospitalCo.,LTD,Yantai264000,China【Abstract】ObjectiveToanalyzetheapplicationeffectofedaravoneanddexborneolinpatientswithacuteischemicstroke(AIS).Methods99patientswithacuteischemicstrokeweredividedintoastudygroup(50cases)andacontrolgroup(49cases)accordingtoarandomnumbertablemethod.Bothgroupsreceivedintravenousthrombolysis,onthisbasis,thecontrolgroupreceivedroutinesymptomatictreatment,whilethestudygroupreceivededaravoneanddexborneoltreatmentonthebasisofthecontrolgroup.Theclinicalefficacy,oxidativestressindex［malondialdehyde(MDA),superoxidedismutase(SOD)］andoccurrenceofadversereactionswerecomparedbetweenthetwogroups.ResultsThetotaleffectiverateofthestudygroupwas94.00%,whichwashigherthan75.51%ofthecontrolgroup(P<0.05).Beforetreatment,therewasnodifferenceinMDAandSODlevelsbetweenthetwogroups(P>0.05).Aftertreatment,thestudygrouphadlowerMDAof(4.55±0.56)μmol/Lthan(6.40±0.89)μmol/Linthecontrolgroup,andhigherSOD...
